End of Day Report – CTIC – Cell Therapeutics, Inc. Added to Russell Indexes – Sourced WhisperFromWallStreet.com
Cell Therapeutics, Inc.,NasdaqCM: CTIC)
7.40 Down 0.46 (5.85%) 3:22pm ET
Last Trade: 1.52
Day’s Range: 1.44 – 1.56
52wk Range: 0.05 – 4.90
Volume: 14,840,176
Cell Therapeutics, Inc. (“CTI”) (Nasdaq and MTA: CTIC) announced recently that it has been added to the Russell 3000(R), Russell 2000(R) and Russell Global(R) Indexes posted by Russell Investments on June 29, 2009 on www.russell.com. Russell Investments reconstitutes its family of U.S. and global equity indexes on an annual basis.
Annual reconstitution of Russell’s U.S. indexes captures the 4,000 largest U.S. stocks as of the last trading day of May, ranking them by total market capitalization. Membership in the Russell 3000(R) Index, which remains in place for one year, means automatic inclusion in the small-cap Russell 2000 Index as well as the appropriate growth and value style indexes. Membership in the Russell Global(R) Index, which remains in place for one year, means automatic inclusion in the appropriate large-cap, small-cap, all-cap indexes as well as the applicable style, sector and country indexes. Russell determines membership for its equity indexes primarily by objective, market capitalization rankings and style attributes.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $4 trillion in assets currently are benchmarked to them. These investment tools originated from Russell’s multi-manager investment business in the early 1980s when the company saw the need for a more objective, market-driven set of benchmarks in order to evaluate outside investment managers.
Total returns data for the Russell Indexes is available at http://www.russell.com/Indexes/performance/default.asp.
About Russell
Russell Investments provides strategic advice, world-class implementation, state-of-the-art performance benchmarks and a range of institutional-quality investment products. Russell had more than $136 billion in assets under management as of March 31, 2009, and serves individual, institutional and advisor clients in more than 40 countries. Founded in 1936, Russell is a subsidiary of The Northwestern Mutual Life Insurance Company.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.
This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of our securities. Specifically, the risks and uncertainties include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and CTI in particular, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing products, CTI’s ability to continue to raise capital as needed to fund its operations, the impact of CTI’s inclusion in the Russell 3000 Index, Russell 2000(R) Index and the Russell Global Index and the risk factors listed or described from time to time in CTI’s filings with the Securities and Exchange Commission including, without limitation, CTI’s most recent filings on Forms 10-K, 10-Q, and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.
